Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 101 publications
Sacituzumab govitecan and stereotactic radiosurgery in the management of HER2 negative breast cancer brain metastases: a multi-institutional report.
Journal: Journal of neuro-oncology
Published: July 31, 2025
Sequencing analysis reveals evidence of immune activation in advanced HER2 negative breast cancer responders treated with entinostat + nivolumab + ipilimumab.
Journal: Research square
Published: June 30, 2025
Correction to: Prognostic impact of ER‑staining patterns and heterogeneity of ER positive HER2 negative breast cancer.
Journal: Breast cancer (Tokyo, Japan)
Published: June 09, 2025
Geographic variation in surgery rates among older patients with early (ER positive HER2 negative) breast cancer: Influence of cardiovascular disease and comorbidities: A national registry dataset analysis.
Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Published: May 29, 2025
Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies.
Journal: Cancer treatment reviews
Published: April 24, 2025
Androgen Receptor Influenced Recurrence Score Correlation in Hormone Positive and HER2 Negative Breast Cancer Indian Patients: A Comparative Approach.
Journal: Genome integrity
Published: December 09, 2024
Prognostic impact of ER-staining patterns and heterogeneity of ER positive HER2 negative breast cancer.
Journal: Breast cancer (Tokyo, Japan)
Published: December 06, 2024
A Review of Current Literature and Real-World Outcomes With Neoadjuvant Chemotherapy in Hormone Receptor Positive, HER2 Negative Breast Cancer.
Journal: Clinical breast cancer
Published: October 14, 2024
Predictive circulating biomarkers of the response to anti-PD-1 immunotherapy in advanced HER2 negative breast cancer.
Journal: Clinical and translational medicine
Published: September 27, 2024
Recurrence score-predicted value derived from estrogen receptor, tumor-infiltrating lymphocytes, progesterone receptor, and Ki-67 may substitute for the Oncotype DX recurrence score in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- breast cancer.
Journal: Annals of diagnostic pathology
Published: September 24, 2024
Capivasertib in combination with fulvestrant in locally advanced or metastatic RH+ HER2- breast cancer with PIK3CA, AKT1 or PTEN alteration, after first-line hormonal therapy
Journal: Bulletin du cancer
Published: August 03, 2024
Neoadjuvant Endocrine Therapy Compared to Neoadjuvant Chemotherapy in Node-Positive HR+, HER2- Breast Cancer (Nodal pCR and the Rate of ALND): A Systematic Review and Meta-Analysis.
Journal: The breast journal
Published: May 23, 2024
Last Updated: 10/31/2025